748,550 Shares in United Therapeutics Corporation $UTHR Acquired by Darwin Global Management Ltd.

Darwin Global Management Ltd. purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 748,550 shares of the biotechnology company’s stock, valued at approximately $317,617,000. United Therapeutics accounts for about 8.8% of Darwin Global Management Ltd.’s holdings, making the stock its 2nd largest holding. Darwin Global Management Ltd. owned approximately 1.74% of United Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AXQ Capital LP boosted its position in United Therapeutics by 495.4% during the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares during the period. AE Wealth Management LLC raised its position in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC raised its position in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc acquired a new position in shares of United Therapeutics during the third quarter worth about $444,000. Finally, Simplify Asset Management Inc. acquired a new position in shares of United Therapeutics during the third quarter worth about $8,351,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Royal Bank Of Canada upped their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, UBS Group lifted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $548.09.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $483.16, for a total value of $4,010,228.00. Following the transaction, the executive vice president directly owned 36,844 shares of the company’s stock, valued at $17,801,547.04. This represents a 18.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Christopher Causey sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total value of $520,000.00. Following the transaction, the director owned 4,190 shares of the company’s stock, valued at approximately $2,178,800. This trade represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 307,930 shares of company stock worth $150,132,812 over the last ninety days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $536.12 on Monday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $548.12. The stock’s 50-day simple moving average is $486.67 and its 200-day simple moving average is $462.28. The firm has a market cap of $23.50 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 1.93 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.19 earnings per share. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.